Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skye Bioscience Inc.

1.57
+0.13509.41%
Post-market: 1.55-0.0200-1.27%19:58 EDT
Volume:568.35K
Turnover:848.85K
Market Cap:48.63M
PE:-2.15
High:1.58
Open:1.40
Low:1.36
Close:1.44
Loading ...

Company Profile

Company Name:
Skye Bioscience Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
16
Office Location:
11250 El Camino Real,Suite 100,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Directors

Name
Position
Punit Dhillon
Chief Executive Officer, Chairman, Director
Andy Schwab
Director
Annalisa Jenkins
Director
Deborah Charych
Director
Keith Ward
Director
Margaret Dalesandro
Director
Paul Grayson
Director
Praveen Tyle
Director

Shareholders

Name
Position
Punit Dhillon
Chief Executive Officer, Chairman, Director
Kaitlyn Arsenault
Chief Financial Officer
Tuan Tu Diep
Chief Development Officer